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In the last two decades, more elaborative use of intensive care units for serious medical disorders,
advancements in transplant procedures and concomitant use of immunosuppressive therapies as well as
the pandemic spread of HIV, etc. have increased the incidence of systemic fungal infections, especially
life threatening central nervous system (CNS) infections.
The CNS fungal infections present with various clinical syndromes: meningitis; encephalitis; hydro-
cephalus/raised intracranial pressure (raised ICP); space occupying lesions; orbito-rhino-cerebral
syndromes; acute cerebro-vascular events and spinal infections. However, the common presentations
among these ones are basal meningitis, hydrocephalus, space occupying lesions (cerebral abscesses and
granulomas) and stroke syndromes. Clinical picture may mimic tubercular meningitis and therefore,
needs careful evaluation.
The CNS mycoses carry higher risks of morbidities and mortality as compared to other infective
processes and therefore promptly require precise diagnosis and appropriate medical and/or surgical
management strategies to optimize the outcome.
Among the antifungal drugs, the Amphotericin B had remained ﬁrst line of therapy for many decades
in invasive fungal infections but is not effective in many forms of mycoses. Fortunately, many useful
antifungal drugs were introduced during the last two decades. Initially, the lipid based formulations of
the Amphotericin B, then the new triazoles and most recently, echinocandins. These medications are
used more frequently in combinations. Now evidence based data are gathering together in favor of their
usefulness in the management of invasive fungal infections. But still, many questions are unanswered
and controversies persist relating to their selection and use.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Fungal infections of the central nervous system (CNS) are rare
clinical entities presenting with protean clinical manifestations,
difﬁcult diagnostic dilemmas and special therapeutic challenges.1,2
Most fungi have low pathogenicity and therefore rarely infect
normal subjects. Contrary to this in recent times, the incidence of
opportunistic CNS mycosis has greatly increased especially in
immunocompromised hosts such as patientswith sepsis, prolonged
ventilation, oncological therapies, organ transplants, extensive use
of antibiotics, HIV, etc.
The CNS fungal infections may present with various clinical
syndromes which may be speciﬁc for certain fungi. Among these,
common syndromes are basal meningitis, hydrocephalus, space
occupying lesions (such as cerebral abscesses, granulomas, etc.)ciates Ltd. Published by Elsevier Ltstroke syndromes (aspergillosis, zygomycosis) and spinal infec-
tions. In general, symptomatic CNS fungal infection carries higher
risks of morbidities and mortality as compared to viral, bacterial,
or parasitic CNS disorders. An early recognition and an appropriate
medical and surgical management strategies are therefore of
paramount importance in improving the overall prognosis in CNS
mycosis.
Still Amphotericin B remained as one of the most useful broad
spectrum antifungal medication but with many toxic side effects
and limitations. Fortunately, during the last two decades, many
useful antifungal drugs were introduced. Initially, the lipid based
formulations of the Amphotericin B, then the new triazoles and
most recently, echinocandins. These medications are used, more
and more effectively in combinations. Initial experiences are
encouraging in favor of their useful roles in the management of
invasive fungal infections. But still, many questions are unan-
swered and controversies are persisting in relation to their
selection and use.d. All rights reserved.
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Generally, Hippocrates is credited with the ﬁrst description of
candidiasis in his book e “epidemics”, in which he described white
patches in the oral cavity of a debilitated patient. The fungal
etiology of these thrushes was established in 1840s by Berg and
Bennett. Zenkar described the ﬁrst case of intracerebral candidiasis
that had died in 1861. In 1792 in his book, Micheli (a priest and
botanist) described Aspergillus to refer to the nine species that
microscopically resembled to aspergillum, a perforated globe
frequently used to sprinkle holy water during religious ceremonies.
However, it was Oppe (1897) who reported the ﬁrst case of rhino-
orbito-cerebral aspergillosis. First case of human zygomycetes
infection was described by Kurchenmeister in 1855 who isolated
non-septate hyphae from a cancerous lung. In 1943, Gregory
described in detail three cases of rhino-cerebral zygomycosis. In
1888, Nocard described an aerobic acid fast actinomycete in cattle
and Eppinger in 1891 reported the ﬁrst case of metastatic (from
lung) cerebral nocardiosis.
Coccidioidomycosis was ﬁrst reported by Alejandro Posadas and
Robert Wernicke in 1892 and in 1905 Ophuls described ﬁrst case of
coccidioidal meningitis. Blastomycosis by Gilchrist (1894), Histo-
plasmosis by Darling (1906), and coccidioidomycosis (South
American Blastomycosis) by Adolfo Lutz in 1908 in Brazil were well
described. Cryptococcuswas reported initially by Buses in 1894 and
later by Fuglemen in 1901.Gonyea reported three patients with
blastomycosis meningitis in 1978.
Many advances have been made in the diagnostic armamen-
tarium of the fungal infections. Medical advancements paralleled
increase in fungal infections as a result of medical therapy of
various diseases and have produced many more cases of immu-
nocompromised status which are prone to opportunistic systemic
mycosis.
3. Epidemiology and classiﬁcation2e6,9,11,13,18e22
Fungal infections are not notiﬁable diseases and precise infor-
mation on their prevalence through out the world is not available.
Although, in general, fungi are cited to be ubiquitous; however,
some forms have a more restricted geographical distribution than
others. More than 100 thousand fungal species are recognized by
now and only a couple of hundreds are found to be pathogenic to
humans. Fortunately, only about 10e15% of pathological fungi
usually produce systemic/CNS mycosis. True pathogenic fungi
(having a restricted geographic distribution, mostly in USA) are
Blastomycetes, Coccidioides, Paracoccidioides, Histoplasma, Spor-
othrix, etc. They produce clinical lesions in normal individuals and
then provide long term immunity to the patients recovered from
the active infections. Whereas the opportunistic fungi (having
ubiquitous distribution) are Aspergillus fumigatus, Candida albicans,
Cryptococcus neoformans, Rhizopus arrhizus, etc. and these provide
no long term immunity to the patients and hence relapses are
noted.
Fungi presents mainly in three forms: moulds (colonies of
branching hyphae-mycelium), yeasts (colonies of single cells) and
intermediate forms. Some fungi are thermodimorphic changing
their forms from mould to yeast under different environmental
conditions. Clinically important true pathogenic dimorphic fungi
are Blastomycetes, Coccidioides, Histoplasma, Sporotrichum and
Paracoccidioides. Cryptococcus remains as an encapsulated yeast in
all environmental conditions.
Fungi are broadly classiﬁed in three major groups as follows:
1. Pseudo-mycetes/yeast—Blastomycetes, Candida, Coccidioides,
Cryptococcus, Histoplasma, Paracoccidioides, Sporotrichum2. Septate mycetes———————Aspergillus, Cephalosporium, Cla-
dosporium, Diplorhinotrichum, Hormodendrum, Paecilomyces,
Penicillium
3. Non-septate mycetes———Absidia, Basidiobolus, Cunning-
hamella, Mucor, Rhizopus
Usually, the inhaled aerosolized fungi initiate a primary mycotic
infection in the lungs and or paranasal sinuses which is usually self-
limiting but may spread to other organs. Frequently, hematogenous
dissemination (from lungs, intestine or prosthetic heart valves)
results in the systemic mycosis and less frequently fungal infections
appear in the CNS.
Direct contiguous spread to the CNS occurs from the paranasal
sinuses, orbits, petro-mastoid region and retro-pharyngeal area in
some patients. Direct implantation may result during the period of
trauma, intensive care procedures and intracranial operations.
Identifying the etiological agent as fungal and not bacterial is vital
since antibacterial therapy is not effective against fungi and CNS
mycoses lead to high morbidity and mortality. Actinomycetes are
bacteria with narrow branched vegetative cells that superﬁcially
resemble fungi. The common ones belong to Nocardia (aerobic) and
Actinomyces (anaerobic) species and therefore, these are also
considered here in this write-up.
4. Pathogenesis2,3,5e7,9,18e28
Fungi profoundly grow in the environment with abundance of
organic matter and water. The enzymes produced by the fungi act
on the organic matter and break down their protein, carbohydrates
and other macromolecules into micro-molecules which are then
easily used by the fungi to maintain their life processes.
Generally, the CNS is regarded as immunological privileged site.
The brain has a specialized, relatively impermeable blood brain
barrier (BBB) and its surrounding sub-arachnoid spaces also have
effective meningeal barriers. These highly vascular structures
provide effective resistance to fungal infections. For immune
surveillance, mainly activated T-lymphocytes are usually permitted
across the BBB in normal individual. However in immune-
compromised states these anatomical and functional barriers are
easily overcome by common (opportunistic and or pathogenic)
fungi to produce clinical manifestations.
Fungal infections of the CNS also evoke humoral and cellular
responses as in bacterial infections with the scope to enable the
host to eliminate the pathogen. Activation of the resident brain cells
by fungi combined with relative expression of immune-enhancing
and immune-suppressing cytokines and chemokines which may
play a determinant role and partially explain the immunopatho-
genesis of CNS fungal infections. Activated resident brain cells such
as microglia, astrocytes and endothelial cells express major histo-
compatibility complex (MHC) Class I and Class II molecules and
therefore act as antigen presenting cells. In addition, they express
complement receptors and produce cytokines, chemokines and
molecules with antifungal activity such as nitric oxide (NO). They
are also capable of phagocytosis. Microglia acting as antigen pre-
senting cells stimulates T-cell proliferation and cytokine secretion
which in turn stimulate these microglial cells to ingest and more
effectively kill invading fungi. The complement (C) system is a key
component of innate immune system, playing a central role in host
defense against pathogens. It is also a powerful drive to initiate
inﬂammation and if unregulated can result in pathological changes
leading to severe tissue damage. It is generally accepted that the C
system is essential to mediate cytolysis of fungi. Furthermore, it is
well known that C-receptors expressed by activated microglial cells
are important to mediate phagocytosis. Immunopathogenesis of
CNS fungal infections in humans is not completely understood. The
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help better understand pathogenesis, virulence and immune
response of host defense against these pathogens. Further studies
in these areas will advance our understanding about CNS mycoses.5. Clinical syndromes of the CNS fungal infections2,5,6,8,12
The CNS fungal infections usually result from pulmonary,
intestinal, cardiac, or craniofacial mycoses and therefore intracra-
nial seedlings occur either during hematogenous dissemination or
by direct extension from the juxta-cranial sites. The CNS mycosis
may be disseminated (cryptococcosis, coccidioidomycosis, etc.),
focal (aspergillosis, zygomycosis, etc.), or multifocal (candidiasis).
Fungi produce diseases due to their allergenicity, toxigenicity,
pathogenicity, neurotoxicity and/or virulence. Fungi producing
distinctive clinical syndromes are found in three major morpho-
logical forms:
1. Small pseudomycetes (yeasts) causing leptomeningitis: Because of
their small size (cryptococcosis, blastomycosis, histoplasmosis,
coccidioidomycosis, etc.) these fungi gain access to the cerebral
microcirculation. From there they seed and infect the CSFand its
containing leptomeninges. Fungi may reach the brain paren-
chyma along the Virchow Robin spaces around the penetrating
and perforating small cortical/cerebral vessels arising from the
major vessels in the sub-arachnoid spaces. Therefore, these
fungi may result in meningitis and or meningo-encephalitis
(Fig. 1).
2. Large pseudomycetes (candidiasis) producing cerebral abscesses
and granulomas: These fungi are larger than 20microns and can
occlude cerebral arterioles. Such occlusions lead to focal cere-
bral ischemia and infarctions. Depending upon the virulence ofFig. 1. A T1 weighted axial MR image following contrast infusion, in a well diagnosed
case of cryptococcal meningitis, showing small multiple enhancing areas in the white
matter in both the cerebral hemispheres representing foci of cryptococcal infection.the fungi and host resistance, variety of the cerebral fungal
lesions appear such as ischemic areas, focal infarctions, cere-
britis, abscesses, granulomas and combinations of these
lesions. The tissue necrosis and highly virulent fungal infection
rapidly convert infected cerebral areas into micro-abscesses.
Whereas a good host resistance but persistence of infection
causes granulomatous inﬂammatory reactions in adjacent
leptomeninges, neural parenchyma or in both sites. This may
result in hydrocephalus which needs to be treated promptly
(Fig. 2).
3. Septate (aspergillosis) and non-septate (zygomycosis) mycetes
are very large in size and normally grow with large branched
hyphae. Usually they infect juxta-cranial sites (paranasal
sinuses, orbits, oral cavity, etc.) for a considerable period of
time and then are capable of invading contiguous cranial bones,
meningeal tissues, basal cerebral venous sinuses, etc. as well as
intermediate and large sized intracranial arteries, and result in
arterial thrombosis and occlusions which in turn causes
extensive cerebral infarctions. These patients clinically present
as the cases of cerebral stroke. The evolving hemorrhagic
cerebral infarct is then converted to septic infarcts with asso-
ciated cerebritis and abscesses whereas a good host defense
result in granuloma formation.
Based on the aforementioned facts, the clinical presentations
of the CNS fungal infections, either alone or in combination, are as
follows:Meningitis; encephalitis; raised intracranial pressure (raised
ICP); mass effect producing parenchymal space occupying lesions
(cerebral cysts, abscesses, granulomas, etc.), orbito-rhino-cerebral
syndromes; acute cerebro-vascular events such as ischemic or
hemorrhagic strokes producing vascular syndromes and spinal
fungal infections. However, common presentations among these
are basal meningitis, space occupying lesions (cerebral abscesses
and granulomas) and hydrocephalus.Fig. 2. A Computed Topographic axial scan in a diagnosed case of extensive paranasal
sinusitis and sino-cranial aspergillosis showing a hyper-attenuation granulomatous
lesion in the right thalamo-mesencephalic region causing hydrocephalus with peri-
ventricular lucencies.
Fig. 3. A computed tomographic axial scan following contrast administration in a case
of disseminated candidiasis showing a right temporal abscess and an occipital abscess,
both, treated with CT guided stereotactic surgery.
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Meningitis, meningo-encephalitis and hydrocephalus:
Chronic fungal meningitis is common, whereas subacute menin-
gitis relatively less common, and the acute fungal meningitis
distinctively rare except in ICU patients or prolonged ventilatory
patients with severely immunocompromised states. Most of the
pseudomycetes (yeasts) are capable of producing meningitis or
meningo-encephalitis. Clinical features of fungal meningitis and
meningo-encephalitis usually are headaches, nausea, vomiting,
visual impairment, and papilledema and later neck stiffness with
fever, personality changes, and then seizures, deterioration in
sensorium, cranial nerve palsies and hydrocephalus. In many
patients, there are no focal or generalized physical signs.
Fungal meningitis ranges from the relatively common crypto-
coccal meningitis to the rare meningitis due to large pseudomy-
cetes (dimorphic) or ﬁlamentous (septate and non-septate) fungi.
Therefore, the fungal meningitis more frequently occurs with
Cryptococcus, Coccidioides, Blastomyces, Paracoccidioides, Sporo-
trichum, Histoplasma and Candida as compared to Filamentous
fungi such as Aspergillus, Cladosporium (Phaeohyphomycosis) and
Zygomycetes.
CNS Cryptococcal infection (European Blastomycosis) usually
presents with typical clinical features of meningitis (subacute or
chronic) or meningo-encephalitis. Acute fatal meningitis is rare in
cryptococcosis; but the periods of remissions and relapses are well
known. Cryptococcosis is one of the most common CNS fungal
infections in immunocompromised patients. Nearly one tenth of
the patients with HIV develop cryptococcosis and in signiﬁcant
number of patients, cryptococcosis manifests as an initial presen-
tation of HIV infection.
Coccidioides is probably the most virulent of the fungi causing
human fungal infections. Meningeal inﬂammation due to fungal
infection results in accumulation of exudates, opaciﬁcation of lep-
tomeninges and obliteration of sulci with caseous granulomatous
nodules at the base of the brain and in the cervical region. Extensive
ﬁbrosis causes obstructive hydrocephalus and invasion of blood
vessels leads tomultiple aneurysms.Unusually largegranulomatous
lesion and frank abscesses may occur in the brain and spinal cord.
In autopsy studies, the most common cerebral mycosis is caused
by candidiasis. Candida albicans originally infects the oral cavity and
esophagus usually following prolonged antibiotic treatment, then
invades sub mucosal blood vessels and ﬁnally disseminates hema-
togenously to the CNS. Candida also reaches CNS via colonization of
the ventricular drains, shunt tubing and central venous lines.
Therefore, Candidal meningitis can occur spontaneously as
a complicationof disseminated candidiasis or as a complicationof an
infected wound or ventriculostomy via direct inoculation of the
organism into the CNS. Usually chronic but infrequently subacute,
basal fungal meningitis causes obliteration of intracranial sub-
arachnoid spaces and results in increased intracranial pressurewith
or without hydrocephalus. All the other major fungi (i.e., histoplas-
mosis, phaeohyphomycosis, and aspergillosis) can also produce life
threatening meningitis and therefore high index of suspicion,
prompt diagnosis and vigorous therapies are required to reduce
morbidities and mortality. In our combined series of 170 patients of
CNS fungal infections,2 six out of 10 patients with CNS candidiasis
and all 21 cases of cryptococcosis had presented primarily with
clinical features of meningitis or meningo-encephalitis; however,
meningitis as a secondarily associated feature was also seen to be
coexisting with other primary CNS manifestations in our cases of
blastomycosis, coccidioidomycosis, aspergillosis, cladosporium,
zygomycosis, nocardiosis and actinomycosis. Cryptococcal and
candiadial meningitis usually respond well to intravenous Ampho-
tericin B therapy with or without ﬂucytosine. In refractory case ofcandidiasis, lipid formulations of Amphotericin B, triazoles and
echinocandins are used. Fluconazole is used as a maintenance
therapy in cryptococcal meningitis in AIDS patients. Triazoles and
Amphotericin B are used against common fungal pathogens with
favorable outcome.
5.2. Intracranial fungal space occupying lesions2e6,23,25,39e51
Intracranial granulomas, abscesses and cysts, especially in the
intraparenchymal locations, form the bulk of the intracranial fungal
space occupying lesions (Sols). Clinically, fungal granulomas are
more frequently diagnosed as compared to fungal abscesses and in
many cases, a mixed picture is seen. Intraparenchymal cysts occur
commonly in basal ganglia in cryptococcal infection as compared to
other mycoses.
Candidiasis, aspergillosis, cryptococcosis, cladosporiosis,
mucormycosis, etc. commonly produce CNS fungal abscesses
(Fig. 3). Fungi disseminating hematogenously from an extra cranial
site cause multiple areas of infection within the brain. Initially, the
meningo-encephalitis occurs with vasculitis-thrombosis and late
hemorrhagic cerebral infarction develops and then an abscess
forms. Abscess forming organisms may progress in a fulminant
fashion leading rapidly to death (Fig. 4). Extremely preterm
neonates and patients with deﬁnitive immunological deﬁciency
syndromes/states are at high risk of developing these complica-
tions with high morbidities and mortality. Unfortunately in many
cases, the diagnosis of these lesions is revealed only at autopsy
(Figs. 5e7).
CNS fungal granulomas are commonly produced by aspergil-
losis, histoplasmosis, blastomycosis, paracoccidioidomycosis, cla-
dosporiasis, mucormycosis, cryptococcosis, etc. Aspergillosis and
mucormycosis of the paranasal sinuses infect the subjacent
meninges and brain parenchyma to produce frontal and temporal
granulomas whereas hematogenous spread of other fungi from
elsewhere produce parietal granulomas in general. Clinical symp-
tomatology depends on fungal infection at the primary location, the
Fig. 4. An axial T1 weighted MR scan in a known fatal case of extensive sino-cranio-
orbital mucormycosis showed a large left pontine abscess with variegated irregular
abscess capsule.
Fig. 6. Postoperative plain axial CT brain scan showing evidence of complete excision
of aspergillotic abscess in the (L) frontal region with some relief in the mass effect and
reversal of the sub-falcine herniation.
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mass effect, etc. Fungal granulomas may resemble tuberculomas
except that they have amore ﬁbrous consistency. Intraparenchymal
cerebral cysts in the basal ganglia some times develop in patients
with cryptococcosis (Fig. 8). In our series of 170 cases, 29 cases had
intracerebral abscesses, 58 cases of cranial & Intracranial granu-
lomas and 13 cases of intra-parenchymatous cryptococcal cysts.2
About 70 patients with primary presentations of the SOL wereFig. 5. An axial plain CT brain scan showed a left frontal abscess with extensive edema
and mass effects with sub-falcine herniation in a case of aspergillosis.subjected to surgical procedures with overall poor prognosis
although it has improved recently due to aggressive interventions
and combination antifungal medications.
Small fungal SOLs are managed with aggressive antifungal
medications and supportive carewhereas signiﬁcantly large lesionsFig. 7. A follow up CT brain scan showed recurrence of left frontal aspergillotic brain
abscess before patient succumbed to his illness.
Fig. 8. A section of a gross pathological specimen in cerebral cryptococcosis showing
extensive involvement of the brain matter by multiple cystic cavities that represented
enlarged Virchow e Robin spaces. Fig. 9. An axial T2 weighted MR image showing extensive involvement of paranasal
sinuses and nasal cavity in a case of aspergillosis.
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surgical interventions. Prognosis depends on the prompt recogni-
tion and management of the life threatening condition.Fig. 10. An axial T2 weighted MR image in a case of aspergillosis showing extensive
involvement of the left orbit with proptosis and paranasal sinuses.5.3. Orbito-rhino-cerebral & skull base syndromes2,4,9,12,42,46,52e57
Fungal infections involving the nasal cavities, paranasal
sinuses, orbits, cranial bones and mandible may extend to cranial
and intracranial structures especially basifrontal and basitemporal
areas (Fig. 9). Long standing fungal sinusitis due to invasive fungi
i.e., Aspergillus, Cladosporium, Zygomycetes (mucormycosis) as
well as fungus like bacteria such as Actinomycetes and Nocardia,
etc. are mainly responsible. Diabetic ketoacidosis is the most
common predisposing factor. According to the involvement of the
anatomical structures (paranasal sinuses, orbits optic nerves,
cranial bone penetration with involvement of intracranial space
and the brain parenchyma) in the skull base region, many types
and combinations of clinical syndromes are named: sino-cranial
(commonest), sino-orbital, sino-orbito-cranial, orbito-cranial,
cavernous sinus, orbital apex, purely orbital syndromes and more
extensive orbito-rhino-cerebral syndromes with associated
speciﬁc and non-speciﬁc symptoms and signs (Fig. 10). Some
patients present purely with cranial mono- or poly-neuropathy.
Each patient must be clinico-radiologically assessed according to
his symptomatology to deﬁne the anatomical extent of the fungal
involvement.
Nasal discharge or blockage with periorbital pains may be the
initial presenting features. Recurrent headaches, proptosis,
impaired ocular movements, progressive visual loss, sensory
impairment in ophthalmic (frequently) andmaxillary (infrequently)
divisions of the trigeminal nerve, chemosis progressing to oph-
thalmoplegia, blindness and periorbital-facial swelling. Headaches,
confusion, irritability, seizures, speech disturbances, focal signs, etc.
herald either direct cerebral involvement or invasion of vascular
structures at the skull base-internal carotids and vertebro-basilar
systems and then overall clinical picture leads to a poor prognosis. In
our series of 170 cases, there were 49 cases of orbito-rhino-cerebralor craniofacial syndromes, mainly due to aspergillosis (18 cases),
zygomycosis (17 cases), actinomycosis (9 cases), nocardiosis
(2 cases), blastomycosis (2 cases) and candidiasis (one case).2
Control of diabetes, radical surgical procedures to the orbit and
paranasal sinuses, neurosurgical intervention for intracranial
infection and aggressive antifungal drug therapy including irriga-
tion of aerated paranasal sinuses with antifungal agents are
needed. Excision of necrotic and infected tissues as well as the
drainage of paranasal sinuses is needed in these patients.
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In CNS fungal infections, acute cerebro-vascular events take the
form of either ischemic (commonly) or hemorrhagic (uncom-
monly) strokes. Aspergillus, Zygomycetes, Candida, Coccidioides,
Histoplasma, Cryptococcus, Penicillium, etc. are all known fungal
infections rarely presenting with acute cerebro-vascular events.
Gradual contiguous involvement of the skull base structures in
cases of prolonged paranasal fungal sinusitis (commonly aspergil-
losis, zygomycosis, cladosporiosis, etc.) leads to angio-invasion
which in turn results in fungal vasculitis and thereafter the
thrombotic occlusions occur in the major branches of the cerebral
vasculature at the skull base: internal carotid arteries and/or ver-
tebro-basilar system. The hyphae invade the vessel walls causing
cerebral arterial thrombosis, cerebral infarction and cerebritis
(Fig. 11). The evolving hemorrhagic infarcts may convert into septic
infarcts.
In cases of major cerebral fungal arteritis in which the direct
surgery is inappropriate, reliance has to be placed on the antifungal
antibiotics and supportive therapy. In our series of 170 patients,
there were 45 cases of major cerebral artery thrombosis especially
either in the ICA or Basilar artery.2 Ischemic cerebral strokes also
result due to cardiac-emboli in patients with fungal endocarditis.
Organisms frequently involved in fungal endocarditis are Candida,
Aspergillosis, etc. However, Candida is the most common causative
organism of fungal endocarditis in, both, immuno-competent and
immunocompromised patients. Rarely, disseminated fungal
cardiac-emboli lodging in the peripheral cerebral vasculature leads
to intracranial fungal mycotic aneurysms, solitary or multiple,
which may present with extremely rare and usually fatal compli-
cations of sub-arachnoid hemorrhage/intracerebral hemorrhage
with and without cerebral infarctions. Intracranial fungal mycotic
aneurysms in the proximal cerebral vasculature (internal carotid
vessels and vertebro-basilar branches) usually result from theFig. 11. An axial CT brain scan showing right basal ganglionic infarction with mass
effect in form of the obliteration of the right frontal horn of lateral ventricle in a case of
right middle cerebral artery occlusion due to invasive mucormycosis from the para-
nasal sinuses.fungal angio-invasion in cases of long standing fungal sinusitis
(aspergillosis, zygomycosis, coccidioidomycosis, etc.). We had six
cases of mycotic aneurysms in our series of 170 cases.2 Apart from
antifungal drug therapy and supportive treatment, if a peripheral
cerebral aneurysm is recognized, it should be excised whenever
possible. However, a direct surgical treatment is usually not
possible in proximal cerebral fungal aneurysms except rarely
endovascular therapy, surgical trapping or peripheral ligations. In
general, the outlook is extremely poor for these patients with CNS
fungal infections presenting with acute strokes.5.5. Spinal fungal infections2e5,12,13,31,68e76
Spinal fungal infections are relatively rare entities and occur
usually in immune-compromised patients and only occasionally in
immune-competent subjects (Fig. 12). These lesions closely mimic
mycobacterial infections and should be considered in the differ-
ential diagnoses of the osteolytic, granulomatous and/or abscess
producing lesions of the spine. The differentiation must be made
using hematological tests including ESR, skin testing (Montoux test,
coccidioidal skin test, etc.), blood cultures, serologic testing (i.e.,
serum anticoccidioidal IgG CFA titer above 1:32), positive cytology,
cultures and histo-pathological examinations of the biopsy speci-
mens, neuro-imaging along with clinical history, etc. Majority of
the destructive lesions usually affect middle/centre of the vertebral
bodies. However, in cases of spinal tuberculosis the posterior
elements are commonly spared whereas in fungal infections
(aspergillosis, blastomycosis, coccidioidomycosis), all spinal
elements may be involved. Spinal column may be affected from
upper cervical to the sacral region; however, upper thoracic level of
the spine is most commonly affected by contiguous spread of the
fungal lesions in the lungs (endemic respiratory fungal pathogense
Aspergillus, Blastomyces, Coccidioides,) and uncommonly involved
due to hematogenous spread (Aspergillus, Candida albicans). Fungal
infections of the spine may present as intradural, extradural and/or
vertebral lesions.
Spinal intradural involvement usually occurs as a part of
generalized cerebro-spinal fungal leptomeningitis but other intra-
dural lesions are extremely rare such as localized spinal meningitis,
spinal arachnoiditis {(aspergillosis, cryptococcosis) presenting as
radiculopathy and or myeloradiculopathy} and fungal myelitis.
Progressive myelopathic syndromes may be due to mass effectFig. 12. An axial computed tomographic scan of the cervical spine showing the
extensive involvement of the subcutaneous tissues and paraspinal muscles in a case of
actinomycosis.
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medullary abscess (Candida albicans), etc. The management
primarily depends on the antifungal drug therapy in these patients
and in only some cases of granulomas/abscesses, where indicated,
neurosurgical decompression is needed.
Extradural and vertebral lesions are relatively more frequent
than the intradural lesions and tend to occur usually in patients
with immune-compromised states (severe systemic disorders with
malnutrition, immune-suppression and organ transplants, HIV
infection, systemic malignancy, uncontrolled diabetes mellitus,
alcohol or intravenous drug abuse, long term antibiotic therapy or
corticosteroid uses and prolonged parenteral nutrition). Hema-
togenous dissemination of fungal infections causes constitutional
symptoms of fever, headache, malaise, anorexia, night sweats,
lethargy, musculoskeletal pains, etc.
In critically ill patients from infancy to old age needing inva-
sive interventions in the intensive care units, candidiasis is
emerging as a frequently diagnosed nosocomial infection due to
hematogenous dissemination with high morbidities and
mortality. Aspergillosis is also a frequent opportunistic infection
(look for chronic paranasal sinusitis) in such cases with impaired
immunity. Blastomycosis is predominantly a granulomatous
cutaneous (look for cutaneous ﬁstulae) or respiratory infection
and then spreads systemically. Coccidioidomycosis (Modeling
Valley Fever) primarily causes benign mildly symptomatic inha-
lational (arthroconidia in the dust in endemic areas) pulmonary
lesions. However, in about 5e10% cases, especially in patients
with compromised cell mediated immunity (such as AIDS, organ
transplants with immuno-suppressants, Hodgkin’s disease,
collagen vascular diseases, etc.), CNS, spinal and musculoskeletal
systems are secondarily involved (look for the nodular skin
lesions and osteolytic skull lesions on the plain X-rays). Multifocal
spinal destructive lesions are common with para-vertebral
involvement (granuloma and abscess formation) especially in the
lower thoracic and upper lumbar regions.
Plain X-rays of the spine show osteolytic, spinal deformities and
instability as well as soft tissue shadow of the paraspinal abscesses
and granulomas. The spinal CT scan demonstrates the ﬁndings seen
on the plain X-rays more clearly as well as shows the surrounding
soft tissue involvement more precisely. MRI scans of the fungal
spondylitis (aspergillosis/candidiasis, etc.) show discal hypo inten-
sity with relative preservation of the intra-nuclear cleft on T2
weighted images, as compared to hyper intensity of the interverte-
bral discs with loss of intra-nuclear cleft in pyogenic spondylitis in
these images. In general, fungal and tubercular granulomatous
lesions cause more pronounced destructive vertebral lesions with
relative sparing of the intervertebral discs in the initial stages of
infection whereas the pyogenic infection destroys, both, the verte-
bral bodies and the discs. In our series of 170 cases, seven patients
had spinal syndrome and 3 patients has fungal craniospinal osteo-
myelitis.2 Once the fungal infection establishes within the spine,
initially the destruction of the vertebrae occurs quite rapidly and
then the intervertebral discs are involved. Multilevel spinal lesions,
spinal column deformities, signiﬁcant para-vertebral lesions, fungal
lesions at junctional regions, spinal cord deformation/compression
and progressive neurological deﬁcits are frequent consequences
needing active neurosurgical management. Neurosurgical arma-
mentarium is consisting of percutaneous CT guided biopsy, opera-
tive debridement of the infected tissues, excision of the
granulomatous lesions, drainage of abscesses, fusion-reconstruc-
tions in cases of spinal destructivedeformities and stabilizationwith
instrumentations in patients with spinal instabilities to maintain
anormalvertebral alignment alongwith theantifungal drug therapy
and supportive care. Overall prognosis is far better as compared to
intracranial fungal infections.6. Antifungal drug therapy and controversies77e84
In the last two decades, more elaborative use of intensive care
units (neonatal and adult) for various serious medical disorders,
advancements in transplant procedures and concomitant use of
immunosuppressive therapies as well as pandemic spread of HIV,
etc. have certainly increased the incidence of systemic fungal
infections especially life threatening or lethal CNS fungal infections.
Reliance only on Amphotericin B was not effective. Fortunately,
during the same period, many useful antifungal drugs were
discovered and introduced. Initially, the lipid based formulations of
the Amphotericin B, then the new triazoles and most recently,
echinocandins. These medications are used, more and more in
combinations, in seriously ill patients with invasive mycoses. Now
evidence based data are gathering together in favor of their
important roles in the management of invasive fungal infections.
But still there are many unanswered questions and controversies
relating to their use. Unquestionably, CNS fungal infections pose
serious challenges in their management with controversies
surrounding their medical and surgical therapies. Surgical options
are less controversial in cases of focal or localized superﬁcial cor-
tico-subcotical lesions (such as abscesses and granulomas) in the
non-eloquent areas of the brain. Whereas invasive multifocal
lesions, deep cerebral and or brain stem lesions, focal lesions
rapidly spreading to involve large parts of the brain and major
vascular invasions are usually not surgically amenable or curable.
Reliance has to be placed heavily on the antifungal drug therapy
along with appropriate surgical options where indicated. Recent
advances in antifungal pharmacotherapy are attempting to provide
drugs with their greater efﬁcacy and lesser toxicity especially in
such invasive CNS fungal infection. Evidence based studies (using
new drugs, singly or in combination) are accumulating and are
assuming greater roles in the management of these serious infec-
tions. Currently following classes of natural and synthetic anti-
fungal drugs are commonly used:
1. Polyenes: Amphotericin B Deoxycholate Complex (Fungizone-
registered, Bristol-Myers Squibb), Nystatin
Lipid formulations of Amphotericin B:
a) AmBisome,
b) Amphocil (Amphotericin B colloidal dispersion {cholesteryl
sulfate}, ABCD)
c) Abelcet (Amphotericin B lipid complex, ABLC)
2. Pyrimidines: 5-ﬂuorocytosine (ﬂucytosine)
3. Triazole drugs: Fluconazole, Itraconazole, Posaconazole,
Voriconazole
4. Echinocandins: Caspofungin, Anidulafungin, Micafungin
5. Miscellaneous: Imidazoles (Clotrimazole, Ketoconazole, etc.),
Oral polyenes (Amphotericin, Nystatin), Griseofulvin, etc. for
dermal, oro-pharyngeal, esophageal, intestinal and vaginal
infections. Terbinaﬁne is effective for nail and ring worm
infections.
Amphotericin is the broad spectrum antifungal drug active
against most fungi: moulds and yeasts. Being a Polyene drug, it is
usually not absorbed through the gastrointestinal tract and is
mainly given intravenously after a test dose (intravenous infusion
of 1 mg over 30 min) before the ﬁrst therapeutic dose (at least
30 min of observation period) to prevent anaphylactic reaction. In
the blood circulation, it is highly protein bound with less pene-
tration in the tissues and body ﬂuids hence behaves like a highly
toxic substance with profound nephrotoxicity.
Lipid formulations of Amphotericin are less protein bound with
more tissue penetration and are less toxic with lesser infusion
related as well as renal side effects. However their clinical
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and are 8e10 times more costly. In patients with pre-existing renal
dysfunctions, obviously, lipid formulations are preferably advised
but same is not justiﬁed in patients with normal renal functions. For
life threatening invasive fungal infections (aspergillosis, zygomy-
cosis, etc.), lipid formulations are initially advised. These medica-
tions are indicated for systemic candidiasis, cryptococcosis and the
endemic mycoses (blastomycosis, histoplasmosis, coccidioidomy-
cosis and paracoccidioidomycosis). In these infections, Amphoter-
icin B and triazole antifungals such as Voriconazole, Fluconazole,
and Posaconazole, are advised either singly or in combinations.
Flucytosine (5-ﬂuorocytosine) is the only commonly used drug
(usually in combination with Amphotericin B) among the pyrimi-
dine class of antifungal drugs especially in infections such as
invasive candidiasis, cryptococcosis, aspergillosis, etc. with signiﬁ-
cant bone marrow toxicity, hepato-toxicity and drug resistance.
Among the azole group of antifungal medications, imidazoles
(miconazole, ketoconazole) are commonly used for localized
surface infections and triazoles (itraconazole-{for dermatophytes
only}, ﬂuconazole, voriconazole, posaconazole) are used for inva-
sive life threatening fungal infections because of their ease of
administration(oral preparations), high bioavailability, water
solubility, low protein binding and a good body ﬂuid distribution,
relatively low toxicity and long half life. A good CSF penetration is
usually achieved. Triazoles have a relatively broad spectrum of
activity against common fungal pathogens e.g., Aspergillus, Blas-
tomyces, Candida, Cryptococcus, Coccidioides, Paracoccidioides, His-
toplasma, etc. However, their limitations lie in the interactions
with co-administered drugs, development of the resistance of
fungal organisms (Candida) especially with ﬂuconazole and hep-
ato-toxicity. Most recently introduced antifungal drugs are Echi-
nocandins (Caspofungin, Anidulafungin, Micafungin) which are
showing promising results in combination antifungal therapy in
the serious opportunistic invasive fungal infections (cadidiasis and
aspergillosis {caspofungin only}). There is a high risk of fungal
infections in immunocompromised patients i.e., long term care in
ICUs (intensive care units), HIV, renal transplant with immuno-
suppresants, etc. Prophylactic antifungal drug therapy using oral
azoles (ﬂuconazole, itraconazole, ketoconazole) is given in such
cases. Fluconazole is the drug of choice for long term use. If fungal
infection is conﬁrmed then the Amphotericin is used initially on
empirical basis. Once the type of the opportunistic fungal infection
is established then the more speciﬁc antifungal drugs are given:
Candidiasis (Triazoles, Echinocandins), Crptococcosis (Amphoter-
icin and Flucytosine in synergistic combination), Aspergillosis
(Amphotericin, Voriconazole, Posaconazole, Caspofungin), Mucor-
mycosis (Amphotericin), etc. Caspofungin is licensed for the
empirical treatment of systemic fungal infections (Candida,
Aspergillus, etc) with neutropenia. Fluconazole is often used in
prevention of the relapse of cryptococcal meningitis in AIDS
patients after completion of primary therapy.
There are many unanswered questions related to the manage-
ment of CNS fungal infections and their medications. Therefore
management controversies are abounding and the available data
do not provide satisfactory answers to questions and controversies.
The factors which play important roles in genesis of these contro-
versies are reported to be personal preferences and experiences of
the treating physicians. There are many pertinent questions such as
follows: 1.Is Amphotericin B still be the ﬁrst line of antifungal
therapy in severely ill immunocompromised patients with CNS
mycoses?; 2. Are lipid formulations of Amphotericin more effective
therapeutically than the Amphotericin B itself?; 3.Which lipid
formulation is better for which type of fungal infection?; 4.Has total
effective therapeutic daily dose of lipid formulations deﬁned?; 5.
Are triazoles replacing Amphotericin B or its lipid formulations?and 6. Echinocandins are more effective when prescribed singly or
perform better in combination therapy?
There are many questions and controversies ranging from the
choice of antifungal medications in CNS mycoses to calculation of
their doses, and the route of administration as well as effective
therapeutic combinations. Only further research and evidence
based data will help resolve these questions and many more
controversies in the management of the CNS fungal infections in
future.
7. Conclusions
Fortunately fungal infections of the CNS are rare as compared to
bacterial and viral infections; however, recently there is an increase
in such infections following relative increase in immunocompro-
mised patient population due to apparent reasons. The CNS fungal
infections present with various clinical syndromes which may be
speciﬁc for certain fungi: meningitis, encephalitis, hydrocephalus/
raised intracranial pressure; mass effect producing space occupying
lesions (cerebral cysts, abscesses, granulomas, etc.); orbito-rhino-
cerebral syndromes; acute cerebro-vascular events and spinal fungal
infections. The common presentations among these are basal
meningitis and or hydrocephalus, space occupying lesions (cerebral
abscesses and granulomas) and stroke syndromes. Clinical picture
may mimic tubercular meningitis and need careful evaluation. The
CNS mycosis carries higher risks of morbidities and mortality as
compared to other infective processes and therefore promptly
requires precise diagnosis and appropriate medical and or surgical
management strategies to optimize the outcomes. Amphotericin B
remained a bench mark medication for such infection. Many useful
antifungal drugs, however, were introduced during the last two
decades. Initially, the lipid based formulations of the Amphotericin
B, then the new triazoles and most recently, echinocandins. These
medications are used more frequently in combinations. Now
evidence based data are gathering together in favor of their useful-
ness in themanagement of invasive fungal infections. But still, many
questions are unanswered and controversies persist relating to their
selection and use. Further research and evidence based data will
help resolve these questions and many more controversies in the
management of the CNS fungal infections in future.
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